Our real-world findings indicate that most patients undergoing multiple lines of therapy experience persistent treatment refractoriness and low response rates,” the researchers wrote.

Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles. Bispecific antibodies are a type of immunotherapy ...

GSK’s Blenrep is the only B-cell maturation antigen (BCMA)-targeted antibody-drug conjugate for multiple myeloma, offering ...

As a marker of minimal residual disease in B-cell acute lymphoblastic leukemia (B-ALL), CD58 has been reported in B-ALL at diagnosis and short-term follow-ups after standard chemotherapies. However, ...

Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its ...

A real-world study has reinforced the efficacy and safety of teclistamab in heavily pretreated patients with ...

A large U.S. registry study of ide-cel CAR-T therapy in relapsed/refractory multiple myeloma shows strong response rates and a safety profile comparable to clinical trials—even among older and ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Cartesian Therapeutics, Inc.’s RNAC share price has dipped by 5.62%, which has investors questioning if this is right time to ...

Legend Biotech (LEGN) shares jumped 5% over the past week on heavy trading volume as investors responded to impressive ...

GSK plc has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Blenrep. In the UK, ...